Business
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing
About this update from Bioxcel Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update. Conference Call & Webcast DetailsDate/Time:Domestic:International:Tuesday, August 9, 2022 at 8:30 AM Eastern Time877-407-5795201-689-8722 The webcast and the accompanying materials will be accessible* under \"News/Events\" on the Investors & Media page of the Company's website at www.bioxceltherapeutics.com. ReplayDomestic:International: Conference ID:877-660-6853201-612-741513731851 *Replay available through November 9, 2022. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company’s commercial product, IGALMI™ (developed as BXCL501), is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. BXCL501 is under investigation for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to c...